Effectiveness and Safety of New Dose of Copaxone® Compared to the Currently Approved Dose

Study Title
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxoneֲ® Compared to Copaxoneֲ® 20mg, the Currently Approved Dose
Teva Identifier
9006
ClinicalTrials.gov Identifier
NCT00202982
Study Status
Completed
Trial Condition(s)
Relapse-Remitting Multiple Sclerosis
Interventions
Drug: glatiramer acetate 20 mg | Drug: glatiramer acetate 40 mg

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 50 Years
Trial Duration
08/01/2003 - 09/01/2005
Phase
Phase 2

Study Type

Interventional